The STAPH score: A predictor of *Staphylococcus aureus* as the causative microorganism of native vertebral osteomyelitis

Takahiro Matsuo\(^1\), Kuniyoshi Hayashi\(^2\), Yuki Uehara\(^{1,3,4,5}\), Nobuyoshi Mori\(^1\)

\(^1\)Department of Infectious Diseases, St. Luke’s International Hospital, Tokyo, Japan

\(^2\)Graduate School of Public Health, St. Luke’s International University, Tokyo, Japan

\(^3\)Department of Clinical Laboratory, St. Luke’s International Hospital, Tokyo, Japan

\(^4\)Department of Microbiology, Juntendo University Faculty of Medicine, Tokyo, Japan

\(^5\)Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan

**Corresponding author:**

Takahiro Matsuo, MD

Department of Infectious Diseases, St. Luke’s International Hospital

9-1, Akashi-cho, Chuo-ku, Tokyo, Japan

Tel: +81-3-3541-5151; Fax: +81-3-3544-0649

E-mail: tmatsuo@luke.ac.jp

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Author contributions:

The manuscript is seen and approved by all authors and not under consideration elsewhere. All authors contributed to the work of this report. TM collected the clinical data and wrote the initial draft of the manuscript. YU and NM assisted in the study conception and design. TM and KH analyzed the data. YU, and NM assisted in the interpretation of results and writing of the manuscript.

Key points:

The STAPH score can predict *Staphylococcus aureus* as the causative microorganism in patients with native vertebral osteomyelitis. Use of the STAPH score among native vertebral osteomyelitis patients might reduce the empirical use of broad-spectrum antimicrobial agents.
Abstract

**Background.** *Staphylococcus aureus* (SA) is the commonest causative microorganism in native vertebral osteomyelitis (NVO). Few studies have compared the clinical features of NVO due to SA (SA-NVO) and NVO due to other organisms (NSA-NVO). This study was conducted to validate a predictive score for SA-NVO to facilitate NVO treatment without broad-spectrum antimicrobial agents.

**Methods.** This retrospective study compared the clinical features of patients with SA-NVO and NSA-NVO, diagnosed from 2004 to 2019. Univariate associations were assessed using chi-square, Fisher’s exact, or Mann–Whitney U test. Multivariable analysis was conducted using logistic regression. The optimal age cutoff point was determined by classification and regression tree analysis.

**Results.** Among 155 NVO patients, 98 (63.2%) had a microbiologically confirmed diagnosis: 40 (25.8%) with SA-NVO and 58 (37.4%) with NSA-NVO. Six predictors, either independently associated with SA-NVO or clinically relevant, were used to develop the STAPH prediction score: Atopic dermatitis (Skin) (3 points); recent Trauma (2 points); Age <67 years (1 point); Abscess (1 point); central venous Port catheter (2 points); and History of puncture (2 points). In a receiver operating characteristic analysis, the area under the curve was 0.84 (95% confidence interval [CI]: 0.76–0.91). The best cutoff point was 3. A score ≥3 had a sensitivity, specificity, positive predictive value, and negative predictive value of 58%, 84%, 84%, and 73%, respectively.

**Conclusions.** The STAPH score has relatively high specificity for use by clinicians to predict SA as the causative microorganism in patients with NVO until results of a confirmatory culture are available.

**Keywords:** native vertebral osteomyelitis, *Staphylococcus aureus*, clinical prediction rule
Introduction

Native vertebral osteomyelitis (NVO) is the main manifestation of hematogenous osteomyelitis in adults [1] and represents 3–5% of all cases of osteomyelitis [2]. The incidence of NVO has been increasing as a result of improved diagnostic techniques, an aging and more immunocompromised population, spinal instrumentation and surgery, and intravenous drug abuse [3,4].

*Staphylococcus aureus* (SA) is the leading cause of NVO [5–7] and is the most commonly isolated NVO organism, accounting for 32–67% of isolates [8]. NVO caused by *S. aureus* (SA-NVO) is associated with a higher infection-related mortality rate and a higher incidence of neurologic complications, such as paraplegia, tetraplegia, and meningitis, associated with paravertebral abscess, especially epidural abscess, than an NVO caused by other microorganisms [9–11]. To our knowledge, there are no scoring systems available to facilitate the prediction, by clinicians, of SA as the causative pathogen of NVO.

Therefore, we aimed to identify the risk factors for SA-NVO and to generate a predictive score that will help to treat NVO without broad-spectrum antimicrobial agents, even when the causative organism is unknown.

Methods

**Study Design and Setting**

We conducted a single-center retrospective cross-sectional study at St Luke’s International Hospital, a 520-bed teaching hospital in Tokyo, from April 2004 to March 2019.

**Inclusion and Exclusion Criteria**

Hospitalized adult patients (age ≥18 years) who presented with vertebral osteomyelitis were included. First, we searched the electronic hospital database for discharge diagnoses of vertebral osteomyelitis. Then, vertebral osteomyelitis was defined through the chart review based on (1) clinical
symptoms such as fever, chills, spinal pain, or localized tenderness; and (2) evidence of spinal bone involvement on magnetic resonance imaging (MRI), including decreased signal intensity in the vertebral body and disk and loss of endplate definition on T1-weighted images, and increased signal intensity of the disk and vertebral body on T2-weighted images. Only the first episode of NVO in a given patient was included.

Patients with vertebral osteomyelitis who had undergone prior spinal surgery, with or without spinal instrumentation or decubitus ulcers, were excluded from this study. The presence of Stage 1 decubitus ulcers alone was not an exclusion criterion. Patients with NVO due to unknown microorganisms were also excluded.

Data Collection

Patient data were extracted from inpatient electronic medical records. The study variables included patient demographics, chief complaints, duration of symptoms, recent history of trauma or puncture procedure, comorbidities, vital signs, physical examinations findings, results of laboratory tests conducted within 24 hours after admission, microbiology results, and complications including infective endocarditis, septic arthritis, and abscess (such as paravertebral, epidural, or psoas muscle) formation confirmed by computed tomography or MRI, neurological sequelae, and mortality.

Variable Definitions

We used the following definitions: “neurological symptoms” included muscle weakness, numbness, and/or tingling sensations; “recent history of puncture” was defined as any needle-using procedure including arthrocentesis, intraarticular injection, injection drug use, or acupuncture; “recent history of trauma” was defined as any injury that had disrupted the skin barrier, including abrasions, stabbing, and penetrating trauma within the previous month; “malignancy” was defined as having received chemotherapy, surgery, or irradiation to treat either a solid tumor or a hematological
malignancy within the previous 6 months; and “abscess” was defined as a paraspinal, epidural, or psoas abscess identified on MRI. For coagulase-negative staphylococci or other possible skin commensals to be considered as a true pathogen, they had to be isolated from at least two blood cultures drawn on separate occasions and/or from a bone biopsy obtained under sterile conditions. Immunosuppressants included systemic corticosteroids, calcineurin inhibitors, antiproliferative drugs such as mycophenolate, mTOR inhibitors, interleukin-2 receptor antibodies, interleukin-6 receptor antibodies, and monoclonal antibodies. Central venous catheters (CVCs) included central venous port catheters (CV ports) and peripherally inserted central catheters (PICCs). Patients with healthcare-associated infections included patients in long-term care facilities, on hemodialysis, and on chemotherapy or total parental nutrition using either CV ports or PICCs.

**Statistical Analyses**

Bivariate associations were assessed using Fisher’s exact test for categorical variables, and the Mann–Whitney U test for continuous variables. The association between individual predictors and the risk of SA-NVO was assessed using a binary multivariable logistic regression model. In general, univariate analysis is performed by the evaluation based strictly on 0.05 significance level, but it seems that multiple variables may have a significant effect on the target outcome by interaction in multivariate analysis. Therefore, as in many previous studies [12,13], we performed a multivariate logistic regression analysis based on the variables with statistical significance of p< 0.1 in this study. The age variable is a continuous value, but in this study, the age variable was binarized by the univariate logistic regression analysis of age and SA, its ROC analysis and obtaining a specific cutoff point for age, and a multivariate logistic regression analysis was performed. Linear regression analysis was also performed to assess whether each item was collinear. Additionally, the logistic regression model was calibrated by plotting the predicted versus the observed probabilities. To evaluate the performance of the proposed model, we estimated the value of the area under the curve (AUC) and its 95% confidence interval (CI) on the ROC plot. A conservative cutoff for the predictive score was
based on the maximization of specificity, as recommended for disease diagnosis. All analyses were performed using SPSS 19.0J statistical software (IBM Japan, Tokyo, Japan).

**Patient Consent Statement**

This study was approved by the Institutional Review Board of St. Luke’s International Hospital in Tokyo, Japan (Number: 19-J025). The requirement for patient consent was waived because the study was based on a retrospective analysis of routinely collected data.

**Results**

**Study Participants**

A total of 156 patients older than 18 years with NVO were hospitalized at St Luke’s International Hospital from 2004 to 2019. Fifty-eight patients were excluded because no causative microorganism was identified, and 98 patients who met the study criteria were included in this study. Forty patients (41%) had SA-NVO [32 patients with methicillin-susceptible *S. aureus* (MSSA) and eight patients with methicillin-resistant *S. aureus* (MRSA)] and 58 patients (59%) had NSA-NVO. Patient characteristics according to the causative pathogen and details of pathogens that were identified are shown at Tables 1 and 2, respectively.

Spinal canal stenosis (30.6%), compression fracture (24.5%), and diabetes mellitus (28.6%) were the commonest comorbidities at diagnosis of NVO among the study participants. Univariate analysis revealed a significantly higher proportion of atopic dermatitis, recent trauma, puncture, and abscess among patients with SA-NVO than those with NSA-NVO. Patients with SA-NVO were more likely to have a CV port than those with NSA-NVO (there were no patients with other central devices such as CVCs or PICCs). The reasons for the use of CV ports were total parenteral nutrition (n=7) and chemotherapy (n=3). There were no significant differences in clinical signs (including vertebral...
tenderness, neurological deficits), duration of symptoms, other comorbidities, and laboratory findings, or complications such as neurological sequelae, infective endocarditis, and septic arthritis between the two groups.

Multivariate analyses revealed that atopic dermatitis, recent history of puncture, and age less than 67 years were independent risk factors for SA-NVO. Recent trauma, abscess, and CV port were associated with SA-NVO, although this association was not statistically significant. Linear regression analysis revealed no collinearity among these parameters. The odds ratios (ORs) of these models were used to obtain representative weights by rounding to develop a score calculated by beta-coefficient on a scale of 0 to 11 for the risk of SA-NVO. We developed a score, which we named the STAPH score, using the variables selected in the multivariate model. These were atopic dermatitis (Skin) (3 points), recent Trauma (2 points), Age <67 years (1 point), Abscess (1 point), CV Port (2 points), and a History of recent puncture (2 points). The results of the multivariate model that was used to determine the score are shown in Table 3.

Figure 1 shows a ROC curve of the STAPH score for the patients with SA-NVO and NSA-NVO. The AUC was 0.84 (95% CI: 0.76–0.91). A score ≥3 had the best value for distinguishing between SA-NVO and NSA-NVO (sensitivity: 58%, specificity: 84%, positive predictive value: 84%, and negative predictive value: 73%).

**Discussion**

To our knowledge, this is the first study to develop a scoring system to predict the presence of SA in patients with NVO. In this study, we determined that atopic dermatitis, age <67 years, and history of puncture were independent predisposing factors for SA-NVO. Furthermore, adding three other clinically important variables, namely recent trauma, presence of an abscess, and presence of a CV port, to the model enabled us to develop the STAPH score to predict SA-NVO with a high degree of specificity. Among the abovementioned factors, age, atopic dermatitis, CV port, and SA infection
were consistently matched with the results of previous studies, whereas a history of trauma, or puncture, and presence of abscesses were new factors.

The prevalence of SA colonization among patients with atopic dermatitis vary widely, and a recent meta-analysis reported a prevalence of 70% for skin with lesions [14]. Thus, SA could contribute to a skin barrier defect and inflammation in atopic dermatitis by different mechanisms, such as the stimulation of mast-cell degranulation by staphylococcal delta toxin, the induction of keratinocyte apoptosis by alpha toxin, and the modulation of inflammation by the staphylococcal surface proteins – protein A and lipoteichoic acid [15–17]. Atopic dermatitis has also been previously reported to be a risk factor for *S. aureus* bacteremia, or infective endocarditis [18–21]. Moreover, CVCs, including CV ports and PICCs, have been reported to be risk factors for SA infection [22,23] and vertebral osteomyelitis [24], consistent with the results of this study.

Few studies have described that a recent history of trauma or puncture could be a risk factor for SA-NVO, although trauma and puncture can cause disruption of the skin barrier and may thus increase the risk of SA-NVO by the same mechanism as in atopic dermatitis or CVCs. Notably, only 2.0% of the participants were injection drug users, which is lower than most studies conducted in Western countries. In contrast, acupuncture, which is an alternative medicine and a frequent practice in Asia, was the most common type of puncture in patients with SA-NVO. Case reports have shown that acupuncture-transmitted infections include vertebral osteomyelitis and subcutaneous abscess [25,26] and, therefore, it is essential for clinicians to consider recent acupuncture to be one of the risk factors for SA-NVO as well as other puncture procedures.

With regard to age, our finding that SA-NVO patients were significantly younger than NSA-NVO patients is also consistent with the findings of some previous studies [27], although some previous studies have not found a significant difference in age between patients with NVO caused by gram-positive cocci and gram-negative bacilli [10,28]. Older patients with NVO may be more likely to have secondary vertebral osteomyelitis following urinary tract infection [24,29], diverticulitis [30], or malignancies [28]. However, younger, previously healthy patients with NVO may be more likely to
have exogenously acquired infections due to trauma or a puncture procedure than endogenous primary infections.

Importantly, our analysis newly revealed that patients with SA-NVO had a higher prevalence of abscess, including paravertebral, epidural, and psoas muscle abscess, than those with NSA-NVO. This result might be because polymorphonuclear leukocytes are responsible for the primary cellular host defense reaction against SA infections and are a major component of abscesses caused by SA [31,32].

Some clinicians may not change their prescription of the initial antimicrobial regimen in patients with NVO, even if they have a high index of suspicion that the patient has SA-NVO. However, if the STAPH score is relatively high, it may prompt these clinicians to search for a metastatic lesion, including infective endocarditis or an abscess [22] while awaiting the culture results. Early initiation of SA-focused treatments, for example, cefazolin and cloxacillin, may also have an earlier bactericidal effect. This is likely to have a positive impact on the outcome, as treatment failure has previously been reported to be associated with delayed diagnosis and treatment [33].

The choice of an empirical antimicrobial therapy is often a challenging issue for clinicians because many different pathogens can cause NVO. The Infectious Diseases Society of America 2015 guidelines of NVO recommend an initial regimen that includes vancomycin in combination with ciprofloxacin, cefepime, or carbapenem for the coverage against staphylococci, including oxacillin-resistant strains, streptococci, and gram-negative bacilli [3]. Clinicians often have trouble with deciding whether to include empirical treatment for gram-negative bacilli, which account for approximately 20% of NVO [34]. From an antimicrobial stewardship perspective, broad-spectrum antimicrobials may induce the creation of multidrug-resistant organisms [35–37] or Clostridioides difficile infection [38–40]. Despite the guideline recommendations for a bone biopsy to determine the causative microorganism [3], a bone biopsy may not be feasible because of patient intolerance or in poorly equipped facilities. Thus, some patients complete a course of broad-spectrum antimicrobial
therapy without the confirmation of the causative microorganism. Obviously, empirical antimicrobial treatment decisions should be based on patient characteristics, clinical circumstances, and epidemiological risk assessment, but it is also important for clinicians to use narrow-spectrum antimicrobial therapy that poses a lower risk of promoting the development of antimicrobial resistance.

This study has several limitations. First, this study was a relatively small single-center observational study conducted. External validation for implementation of the STAPH score by comparison with patients with NVO at other hospitals and prospective validation of the results of this study are warranted. Second, this STAPH score did not assess whether MSSA and MRSA could be the causative pathogens of NVO. As in previous studies [11,41,42], most SA isolates from patients in this study were MSSA, and only 20% of SA strains were methicillin resistant. The STAPH score might be useful to alert clinicians that SA could be the causative organism, to engender further discussion about whether the initial treatment should cover MRSA in addition to MSSA, depending on its regional prevalence and risk factors such as recent MRSA infections, prior antibiotic use [43,44], or injectable drug use [45]. Further studies in the regions where the prevalence of MRSA is higher than in Japan are warranted. Third, a relatively large number of patients were excluded in this study because of NVO caused by unknown pathogens. This could be explained by the lower proportion of biopsy. A potential sampling bias could exist. Finally, assessment and recording of neurological symptoms, recent puncture history, and recent trauma is likely to vary among clinicians, and it is possible some of the clinical variables were underreported in the medical records and the subsequent analysis. Although the limited data from a single center does not allow for generalization, the estimation of SA by this score may demonstrate the usefulness of the STAPH Score, as the causative organism is often unknown because a bone biopsy for pathogen identification is not always possible.
Conclusion

We developed a simple STAPH score to help predict whether cases of NVO are caused by SA. The STAPH score may help clinicians to predict that SA is the causative microorganism in patients with NVO before the confirmatory culture results become available, and in cases where the causative organism cannot be identified.

Potential conflicts of interest:

No conflict

Acknowledgments

We highly appreciate Dr. Nicholas Rennick who helped develop the STAPH score.

Funding Sources

None

Grant numbers

None

Data availability

Data not publicly available.
References

1. Gouliouris T, Aliyu S, Brown N. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother 2010; 65:iii11–24.

2. Jensen AG, Espersen F, Skinhøj P, Rosdahl VT, Frimodt-Møller N. Increasing frequency of vertebral osteomyelitis following Staphylococcus aureus bacteraemia in Denmark 1980–1990. J Infect 1997; 34:113–118.

3. Berbari EF, Kanj SS, Kowalski TJ, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice Guidelines for the Diagnosis and Treatment of Native Vertebral Osteomyelitis in Adults. Clin Infect Dis 2015; 61:e26–46.

4. Ozuna RM, Delamarter RB. Pyogenic vertebral osteomyelitis and postsurgical disc space infections. Orthop Clin North Am 1996; 27:87–94.

5. Mylona E, Samarkos M, Kakalou E, Fanourgiakis P, Skoutelas A. Pyogenic vertebral osteomyelitis: A systematic review of clinical characteristics. Semin Arthritis Rheum 2009; 39:10–17.

6. Chang W-S, Ho M-W, Lin P-C, et al. Clinical characteristics, treatments, and outcomes of hematogenous pyogenic vertebral osteomyelitis, 12-year experience from a tertiary hospital in central Taiwan. J Microbiol Immunol Infect 2018; 51:235–242.

7. Rivero C, Jahan C, Dapás JI, Vila A. Clinical and microbiological features of native vertebral osteomyelitis (NVO) in adults: a retrospective analysis from a private hospital of Mendoza, Argentina. Int J Infect Dis 2018; 73:151.

8. Mylona E, Samarkos M, Kakalou E, et al. Pyogenic vertebral osteomyelitis: a systematic review of clinical characteristics. Semin Arthritis Rheum 2009; 39:10–7.

9. Pigrau C, Almirante B, Flores X, et al. Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome. Am J Med 2005; 118:1287.
10. Park K-H, Cho OH, Jung M, et al. Clinical characteristics and outcomes of hematogenous vertebral osteomyelitis caused by gram-negative bacteria. J Infect 2014; 69:42–50.

11. Gupta A, Kowalski TJ, Osmon DR, et al. Long-term outcome of pyogenic vertebral osteomyelitis: A cohort study of 260 patients. Open Forum Infect Dis 2014; 1:ofu107–ofu107.

12. Marschall J, Bhavan KP, Olsen MA, Fraser VJ, Wright NM, Warren DK. The impact of prebiopsy antibiotics on pathogen recovery in hematogenous vertebral osteomyelitis. Clin Infect Dis 2011; 52(7):867–872.

13. Bhanji F, Topjian AA, Nadkarni VM, et al. Survival rates following pediatric in-hospital cardiac arrests during nights and weekends. JAMA Pediatr 2017; 171(1):39.

14. Totté JEE, van der Feltz WT, Hennekam M, van Belkum A, van Zuuren EJ, Pasmans SGMA. Prevalence and odds of Staphylococcus aureus carriage in atopic dermatitis: a systematic review and meta-analysis. Br J Dermatol 2016; 175:687–695.

15. Nakamura Y, Oscherwitz J, Cease KB, et al. Staphylococcus δ-toxin induces allergic skin disease by activating mast cells. Nature 2013; 503:397–401.

16. Brauweiler AM, Bin L, Kim BE, et al. Filaggrin-dependent secretion of sphingomyelinase protects against staphylococcal α-toxin–induced keratinocyte death. J Allergy Clin Immunol 2013; 131:421–427.

17. Giai C, Gonzalez C, Ledo C, et al. Shedding of tumor necrosis factor receptor 1 induced by protein a decreases tumor necrosis factor alpha availability and inflammation during systemic staphylococcus aureus infection. Infect Immun 2013; 81:4200–4207.

18. Benenson S, Zimhony O, Dahan D, et al. Atopic dermatitis—a risk factor for invasive Staphylococcus aureus infections: Two cases and review. Am J Med 2005; 118:1048–1051.
19. Wanke I, Skabytska Y, Kraft B, Peschel A, Biedermann T, Schittek B. Staphylococcus aureus skin colonization is promoted by barrier disruption and leads to local inflammation. Exp Dermatol 2013; 22:153–155.

20. Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347:1151–1160.

21. Berents TL, Carlsen KCL, Mowinckel P, et al. Skin barrier function and Staphylococcus aureus colonization in vestibulum nasi and fauces in healthy infants and infants with eczema: A population-based cohort study. PLoS One 2015; 10:e0130145.

22. Horino T, Sato F, Hosaka Y, et al. Predictive factors for metastatic infection in patients with bacteremia caused by methicillin-sensitive Staphylococcus aureus. Am J Med Sci 2015; 349:24–28.

23. Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2001; 22:222–242.

24. Mylona E, Samarkos M, Kakalou E, Fanourgiakis P, Skoutelis A. Pyogenic vertebral osteomyelitis: A systematic review of clinical characteristics. Semin Arthritis Rheum 2009; 39:10–17.

25. Woo PCY, Lau SKP, Wong SSY, Yuen KY. Staphylococcus aureus subcutaneous abscess complicating acupuncture: need for implementation of proper infection control guidelines. New Microbiol 2003; 26:169–74.

26. He C, Wang T, Gu Y, Tian Q, Zhou B, Wu C. Unusual case of pyogenic spondylodiscitis, vertebral osteomyelitis and bilateral psoas abscesses after acupuncture: Diagnosis and treatment with interventional management. Acupunct Med 2015; 33:154–157.
27. Lee C-Y, Wu M-H, Cheng C-C, et al. Comparison of gram-negative and gram-positive hematogenous pyogenic spondylodiscitis: clinical characteristics and outcomes of treatment. BMC Infect Dis 2016; 16:735.

28. Graham SM, Fishlock A, Millner P, Sandoe J. The management gram-negative bacterial haematogenous vertebral osteomyelitis: a case series of diagnosis, treatment and therapeutic outcomes. Eur Spine J 2013; 22:1845–1853.

29. Doutchi M, Seng P, Menard A, et al. Changing trends in the epidemiology of vertebral osteomyelitis in Marseille, France. New Microbes New Infect 2015; 7:1–7.

30. Van Dam H, Lange JF. Diverticulitis of the sigmoid colon complicated by vertebral osteomyelitis. Eur J Surg 1996; 162:661–663.

31. Kobayashi SD, Malachowa N, DeLeo FR. Pathogenesis of Staphylococcus aureus abscesses. Am J Pathol 2015; 185:1518–1527.

32. Cheng AG, DeDent AC, Schneewind O, Missiakas D. A play in four acts: Staphylococcus aureus abscess formation. Trends Microbiol 2011; 19:225–232.

33. Fukuchi T, Iwata K, Ohji G. Failure of early diagnosis of infective endocarditis in Japan—a retrospective descriptive analysis. Medicine (Baltimore) 2014; 93:e237.

34. Bhavan KP, Marschall J, Olsen MA, Fraser VJ, Wright NM, Warren DK. The epidemiology of hematogenous vertebral osteomyelitis: a cohort study in a tertiary care hospital. BMC Infect Dis 2010; 10:158.

35. Hamprecht A, Rohde AM, Behnke M, et al. Colonization with third-generation cephalosporin-resistant Enterobacteriaceae on hospital admission: prevalence and risk factors. J Antimicrob Chemother 2016; 71:2957–2963.
36. Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014; 58:5262–5268.

37. Gross AE, Van Schooneveld TC, Olsen KM, et al. Epidemiology and predictors of multidrug-resistant community-acquired and health care-associated pneumonia. Antimicrob Agents Chemother 2014; 58:5262–5268.

38. Brown K, Valenta K, Fisman D, Simor A, Daneman N. Hospital ward antibiotic prescribing and the risks of Clostridium difficile infection. JAMA Intern Med 2015; 175:626.

39. Pepin J, Saheb N, Coulombe M-A, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: A cohort study during an epidemic in Quebec. Clin Infect Dis 2005; 41:1254–1260.

40. Deshpande A, Pasupuleti V, Thota P, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68:1951–1961.

41. Loibl M, Stoyanov L, Doenitz C, et al. Outcome-related co-factors in 105 cases of vertebral osteomyelitis in a tertiary care hospital. Infection 2014; 42:503–510.

42. Aguilar-Company J, Pigrau C, Fernández-Hidalgo N, et al. Native vertebral osteomyelitis in aged patients: distinctive features. An observational cohort study. Infection 2018; 46:679–686.

43. Shorr AF. Epidemiology of staphylococcal resistance. Clin Infect Dis 2007; 45:S171–S176.

44. Furuno JP, McGregor JC, Harris AD, et al. Identifying groups at high risk for carriage of antibiotic-resistant bacteria. Arch Intern Med 2006; 166:580.

45. Jackson KA, Bohm MK, Brooks JT, et al. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs — six sites, 2005–2016. MMWR Morb Mortal Wkly Rep 2018; 67:625–628.
Figure legend

Figure 1. The receiver operating characteristic curve of the STAPH score.
Table 1. Patient characteristics according to the type of native vertebral osteomyelitis

|                                | SA-NVO (n=40) | NSA-NVO (n=58) | p-value |
|--------------------------------|---------------|---------------|---------|
| Sex (male), n (%)              | 22 (55)       | 35 (60.3)     | 0.374   |
| Age, median (IQR)              | 59 (49.8–74)  | 73 (58.5–79.5)| 0.006   |
| Vertebral knock pain, n (%)    | 38 (95)       | 51 (87.9)     | 0.200   |
| Neurological deficit, n (%)    | 15 (37.5)     | 14 (24.1)     | 0.116   |
| Duration of symptoms (days), median (IQR) | 5 (2.0–12.5) | 6.5 (2–18.5) | 0.194   |
| Atopic dermatitis, n (%)       | 10 (25)       | 1 (1.7)       | 0.001   |
| Recent history of trauma, n (%)| 6 (15)        | 2 (3.4)       | 0.048   |
| Recent history of puncture, n (%) | 11 (27.5)   | 3 (5.2)       | 0.002   |
| Diabetes, n (%)                | 12 (30)       | 16 (27.6)     | 0.173   |
| Malignancy, n (%)              | 3 (7.5)       | 9 (15.5)      | 0.192   |
| Compression fracture, n (%)    | 10 (25)       | 14 (24.1)     | 0.329   |
| Spinal stenosis, n (%)         | 13 (32.5)     | 17 (29.3)     | 0.450   |
| Hemodialysis, n (%)            | 2 (5.0)       | 4 (6.9)       | 0.527   |
| Immunosuppressant, n (%)       | 6 (15.0)      | 8 (13.8)      | 0.545   |
| Chemotherapy, n (%)            | 0 (0)         | 2 (3.4)       | 0.348   |
| CV port, n (%)                 | 7 (17.5)      | 3 (5.2)       | 0.051   |
| Healthcare-associated, n (%)   | 10 (25)       | 14 (24.1)     | >0.99   |
| Temperature (°C), median (IQR) | 37.5 (4.8–15)| 37.4 (4.9–16)| 0.761   |
| Systolic blood pressure (mmHg), median (IQR) | 122 (100–148) | 128 (110–142) | 0.567   |
| Pulse rate (/minute), median (IQR) | 86 (62–112)  | 80 (58–110)  | 0.622   |
| Respiratory rate (/minute), median (IQR) | 22 (15–26)  | 21 (14–28)  | 0.819   |
| SpO₂ (%), median (IQR)         | 96 (92–99)    | 96 (91–99)    | >0.99   |
| Blood urine nitrogen (mg/dL), median (IQR) | 18 (12–25)  | 16 (12–26)  | >0.99   |
| Creatinine (mg/dL), median (IQR) | 0.68 (0.41–1.1)| 0.76 (0.4–1.5)| 0.472   |
| White blood cell count (/µL), median (IQR) | 12.6 (4.9–16) | 12.4 (5.1–15.4) | 0.791   |
| CRP (mg/dL), median (IQR)      | 13.2 (4.22–25.7)| 9.7 (4.4–17.6)| 0.188   |
|                                | Median (IQR)          |          |
|--------------------------------|-----------------------|----------|
| **ESR (mm/hour), median (IQR)**| 70 (43–100)           | 61.5 (44.2–89.8) |
| **HbA1c (%), median (IQR)**    | 5.8 (5.5–6.3)         | 5 (2–12.5) |
| **Site of infection**          |                       |          |
| Cervical, n (%)                | 6 (15.0)              | 10 (17.2) |
| Thoracic, n (%)                | 7 (17.5)              | 8 (13.8)  |
| Lumbar, n (%)                  | 19 (47.5)             | 24 (41.4) |
| Sacral, n (%)                  | 2 (5.0)               | 0 (0)     |
| Cervicothoracic, n (%)         | 2 (5.0)               | 7 (12.1)  |
| Thoracolumbar, n (%)           | 4 (10.0)              | 7 (12.1)  |
| Lumbosacral, n (%)             | 0 (0)                 | 1 (1.7)   |
| Thoracolumbosacral, n (%)      | 0 (0)                 | 1 (1.7)   |
| **Bone biopsy or pus drainage**| 10 (20.8)             | 17 (29.3) |
| **Bone or pus culture positive, n (%)**| 6 (15.0) | 15 (25.9) |
| **Blood culture positive, n (%)**| 38 (95.0)          | 48 (82.8) |
| **Abscess (paravertebral, epidural, or psoas muscle), n (%)**| 36 (90) | 40 (69.0) |
| **Infective endocarditis, n (%)**| 7 (17.5)     | 8 (13.8)  |
| **Septic arthritis, n (%)**    | 4 (10.0)              | 6 (10.3)  |
| **Length of treatment IV, median (IQR)** | 42 (72) | 43 (137)  |
| **Length of treatment PO, median (IQR)** | 59 (249) | 59 (510) |
| 30-day mortality, n (%)        | 0                    | 0         |
| 90-day mortality, n (%)        | 2 (5.0)              | 1 (2.5)   |
| Neurological sequelae          | 6 (15.0)             | 4 (6.9)   |
| 1-year recurrence, n (%)       | 1 (2.5)              | 2 (5.0)   |

Abbreviations: CRP, C-reactive protein; CV port, central venous port; ESR, erythrocyte sedimentation rate; HbA1c, glycated hemoglobin; SpO₂, oxygen saturation measured by pulse oximeter, IV: intravenous, PO: per os
Table 2. Details of pathogens identified (n=98)

| Pathogen                                      | Number |
|-----------------------------------------------|--------|
| **Gram-positive**                             | 86     |
| *Staphylococcus aureus*                       |        |
| Methicillin-sensitive                         | 32     |
| Methicillin-resistant                         | 8      |
| Coagulase-negative *Staphylococcus*           | 9      |
| *Staphylococcus pneumoniae*                   | 1      |
| Viridans group streptococci                   | 10     |
| **Beta-hemolytic streptococci**               |        |
| *Streptococcus pyogenes*                      | 3      |
| *Streptococcus agalactiae*                    | 12     |
| *Streptococcus dysgalactiae*                  | 3      |
| *Enterococcus spp*                            | 2      |
| *Parvimonas micra*                            | 1      |
| *Cutibacterium acnes*                         | 4      |
| **Gram-negative**                             | 13     |
| *Escherichia coli*                            | 4      |
| *Klebsiella* spp.                             | 3      |
| Nontyphoidal *Salmonella* spp.                 | 3      |
| *Serratia* spp.                               | 1      |
| *Bacteroides fragilis*                        | 2      |
Table 3. Results of the multivariate logistic regression analysis used to determine the STAPH score for predicting a staphylococcal vertebral infection

|                          | Adjusted OR | Beta-coefficient | 95% CI     | p-value | Points |
|--------------------------|-------------|------------------|------------|---------|--------|
| Skin: atopic dermatitis  | 15.7        | 2.8              | 1.7–145    | 0.015   | 3      |
| Trauma                   | 4.9         | 1.6              | 0.75–31.8  | 0.096   | 2      |
| Age <67 years            | 3.1         | 1.1              | 1.1–8.6    | 0.031   | 1      |
| Abscess                  | 3.0         | 1.1              | 0.78–11.2  | 0.111   | 1      |
| CV Port                  | 5.1         | 1.6              | 0.98–26.7  | 0.053   | 2      |
| History of puncture      | 7.0         | 1.9              | 1.44–29.1  | 0.019   | 2      |

Abbreviations: CV Port, central venous port.

The STAPH score is based on the six items shown in the left column. One to three points are assigned to each item (shown in the right column), based on rounding of the beta-coefficient value, for a maximum possible score of 11.
Figure 1

Area under curve: 0.84
(95% CI 0.76–0.91)